This research discusses the issues patients face when managing, treating, and controlling their diabetes over the long term. It also points to the need for a more integrated Canadian health system.
Accessing Diabetes Medications: A Pan-Canadian Analysis of Patient Experiences
Accessing Diabetes Medications: A Pan-Canadian Analysis of Patient Experiences
$0.00
Medicines are a key component of a range of therapeutic interventions that Canadians use to prevent, manage, and cure health conditions. Patients living with diabetes depend on access to evidence-based, individualized treatments to maintain and improve their health outcomes, reduce complications, and increase overall quality of life and lifespan.
As part of a broader research agenda exploring options for universal pharmacare in Canada, Signal49 Research completed research on how patients with diabetes access necessary medications. Accessing Diabetes Medications: A Pan-Canadian Analysis of Patient Experiences discusses the issues patients face when managing, treating, and controlling their health conditions over the long term. It also points to the need for a more integrated health system focused on outcomes that are meaningful to patients. To this end, it is essential that these outcomes be measured and assessed in a standardized way, and used as the basis for continuous quality improvement efforts.
Effective January 26, 2026, AERIC Inc./Signal49 Research discontinued use of ‘The Conference Board of Canada’ name, logo and branding, which had been used by AERIC Inc./Signal49 Research under license from The Conference Board, Inc. The Conference Board, Inc. and its licensees, which are not affiliated with Signal49 Research, own all right, title and interest in THE CONFERENCE BOARD name and trademarks in Canada and have the exclusive right to their use in Canada since January 26, 2026.
